GlassScriptPhysician profile
Sarah A Walker
NPI 1184177487
$1,829.12
in general payments reported to CMS, 2019-2025
24 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $207 · 2022: $518 · 2023: $462 · 2024: $330 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,004.49 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $423.02 | 2021-2025 | Nemluvio |
| Genzyme Corporation | $182.72 | 2023-2025 | |
| Incyte Corporation | $174.51 | 2022-2024 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $170.04 | 2024-2025 | Jublia, Cabtreo, Siliq |
| Abbvie INC. | $160.67 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $132.24 | 2022-2025 | Absorica Ld, Winlevi |
| Amgen INC. | $113.03 | 2021-2023 | Enbrel, Otezla |
| Janssen Biotech, INC. | $88.00 | 2022-2023 | Remicade, Simponi Aria, Simponi |
| Lilly USA, LLC | $53.45 | 2023-2024 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $36.00 | 2023 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.69 | 2023 | Spevigo |
| Allergan, INC. | $31.29 | 2021 | |
| Leo Pharma INC. | $31.17 | 2021-2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $30.63 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $22.05 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $21.98 | 2025 | Bimzelx |
| Epi Health, LLC | $20.64 | 2021 | |
| Vyne Pharmaceuticals INC. | $17.67 | 2021 | |
| Botanix Sb INC | $17.25 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $17.08 | 2022 | |
| Arcutis Biotherapeutics, INC. | $16.83 | 2024 | Zoryve |
| Dermavant Sciences, INC. | $13.74 | 2023 | Vtama |
| Journey Medical Corporation | $12.81 | 2022 | |
| Biofrontera INC. | $9.61 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.